MRD HSCT
Showing 1 - 25 of 1,343
ALL, MRD-positive, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Inotuzumab Ozogamicin)
Recruiting
- ALL
- +2 more
- Inotuzumab Ozogamicin
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jul 14, 2023
Acute Lymphoblastic Leukemia Trial in Hangzhou (Blinatumomab)
Recruiting
- Acute Lymphoblastic Leukemia
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Nov 5, 2023
Prophylactic HQP1351 Therapy, Third Generation TKI Trial in Guanzhou (HQP1351( Olverembatinib dimesylate))
Withdrawn
- Prophylactic HQP1351 Therapy
- Third Generation TKI
- HQP1351( Olverembatinib dimesylate)
-
Guanzhou, ChinaDepartment of Hematology, Nanfang Hospital, Southern Medical Uni
Jan 16, 2023
Digital Droplet PCR in Early Period After Allo-HSCT to Predict
Completed
- Measurable Residual Disease
- Digital Droplet PCR
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 17, 2023
MDS, Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts, Mixed Myelodysplastic/Myeloproliferative
Recruiting
- Myelodysplastic Syndromes
- +2 more
- Azacitidine
- +2 more
-
Stockholm, SwedenDepartment of Hematology, Karolinska University Hospital
Mar 27, 2023
AML Trial in Moscow (allo-HSCT)
Recruiting
- AML
- allo-HSCT
-
Moscow, Russian FederationNational Research Center for Hematology
Apr 14, 2022
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Minneapolis (HSCT with TBI Regimen, HSCT with
Recruiting
- Acute Leukemia
- +27 more
- HSCT with TBI Regimen
- HSCT with Non-TBI Regimen
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Apr 12, 2022
Hematologic Malignancy, Stem Cell Transplant Complications Trial in Hangzhou (Azacitidine in Combination With Venetoclax)
Recruiting
- Hematologic Malignancy
- Stem Cell Transplant Complications
- Azacitidine in Combination With Venetoclax
-
Hangzhou, Zhejiang, ChinaThe first Affiliated Hospital of Zhejiang University
Mar 24, 2021
ALL, Childhood, Minimal Residual Disease Trial in Worldwide (Blinatumomab)
Recruiting
- ALL, Childhood
- Minimal Residual Disease
-
Vienna, Austria(AUT), Austria
- +14 more
Mar 4, 2021
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Cytarabine
- +4 more
-
Birmingham, Alabama
- +8 more
Jan 24, 2023
Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease Trial in Tianjin (the usage of Olverembatinib combined with Inotuzumab
Not yet recruiting
- Ph+ ALL
- +2 more
- the usage of Olverembatinib combined with Inotuzumab Ozogamicin
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital, Chinese Acade
Oct 30, 2022
Myeloid Leukemia, MDS Trial (IFN-?)
Not yet recruiting
- Myeloid Leukemia
- Myelodysplastic Syndromes
- (no location specified)
Nov 15, 2023
Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse Trial in Beijing (Decitabine, mBU/CY and ATG,
Recruiting
- Stem Cell Transplant Complications
- +2 more
- Decitabine
- +2 more
-
Beijing, Beijing, ChinaPeking University Institute of Hematology,Beijing
Mar 9, 2020
B-cell Adult Acute Lymphoblastic Leukemia, Stem Cell Leukemia, Minimal Residual Disease Trial in Vancouver, Halifax
Terminated
- B-cell Adult Acute Lymphoblastic Leukemia
- +2 more
- blinatumomab
-
Vancouver, British Columbia, Canada
- +2 more
Feb 3, 2022
Minimal Residual Disease, Donor Lymphocyte Infusion, Hematopoietic Stem Cell Transplantation Trial in Guangzhou (donor
Completed
- Minimal Residual Disease
- +3 more
- donor lymphocyte infusion
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
Feb 24, 2020
Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia Trial (GVHD prevention: post-transplantation
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +5 more
- GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
- (no location specified)
Aug 23, 2022
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma Trial in San Diego,
Completed
- Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood B-Lymphoblastic Lymphoma
- dexamethasone
- +18 more
-
San Diego, California
- +2 more
Sep 13, 2022
T Lymphoblastic Leukemia/Lymphoma Trial in Hangzhou (Chidamide)
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 7, 2023
Acute Myeloid Leukemia, Stem Cell Transplantation Trial in United States (MT-401)
Recruiting
- Acute Myeloid Leukemia
- Stem Cell Transplantation
-
Birmingham, Alabama
- +15 more
Aug 22, 2022
Acute Lymphoblastic Leukemia, Pediatric, ALL, Infants Trial (the risk-adapted choice of therapy and the use of a combination of
Not yet recruiting
- Acute Lymphoblastic Leukemia, Pediatric
- ALL, Infants
- the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
- (no location specified)
Aug 26, 2021
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult Trial in Xi'an
Recruiting
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- +2 more
-
Xi'an, Shaanxi, ChinaFirst Affiliated Hospital of Xian Jiaotong University
Sep 29, 2021
Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))
Recruiting
- Mixed Phenotype Acute Leukemia (MPAL)
- Measurable Residual Disease (MRD)
- BLINCYTO (Blinatumomab)
-
Baltimore, MarylandGreenebaum Cancer Center at University of Maryland Medical Cente
Apr 18, 2022
Acute Lymphoblastic Leukemia Trial in Spain (Pediatric-type of chemo, allogeneic HSCT)
Recruiting
- Acute Lymphoblastic Leukemia
- Pediatric-type of chemotherapy
- allogeneic HSCT
-
Badalona, Barcelona, Spain
- +107 more
Feb 17, 2022